首页> 外文OA文献 >BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3

【2h】

BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3

机译：BMET-13。 Ceritinib在ALK抑制剂（ALKI）中的全身和颅内疗效 - 患有ALK重新排列（ALK +）NSCLC和基线脑转移（BM）的患者：Ascend-1和-3的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ranee Mehra; Enriqueta Felip; Daniel Shao-Weng Tan; Dong-Wan Kim; Sergey Orlov; Keunchil Park; Chong-Jen Yu; Tony Mok; Makoto Nishio; Giorgio V. Scagliotti; David R. Spigel; Santosh Sutradhar; Dajana Cesic; Alice Tsang Shaw;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC [J] . Nishio Makoto, Felip Enriqueta, Orlov Sergey, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2020,第4期

机译：Ascend-3的最终总体存活和其他疗效和安全结果：AlK-Naivive患者Ceritinib的II期研究ALK-Reallanged NSCLC
2. PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) [J] . Gilberto De Castro, Daniel Shao-Weng Tan, Lucio Crinò, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PL03.07：ALK重新排列（ALK +）NSCLC患者的一线Ceritinib与化疗：随机，第3阶段研究（Ascend-4）
3. PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) [J] . Gilberto De Castro, Daniel Shao-Weng Tan, Lucio Crinò, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PL03.07：ALK重新排列（ALK +）NSCLC患者的一线Ceritinib与化疗：随机，第3阶段研究（Ascend-4）
4. BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL [O] . Alice Shaw, Ranee Mehra, Daniel S.W. Tan, 2014

机译：BM-32CERITINIB（LDK378）用于治疗ASCEND-1试验中发生了ALK变种（ALK +）非小细胞肺癌（NSCLC）和脑转移瘤（BM）的患者
5. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials [O] . E. Felip, L. Crinò, D.-W. Kim, 2016

机译：141PD：Ceritinib在患者（PTS）中的全身和颅内疗效，用克里齐替尼（CRZ）预处理，ALK重新排列（ALK +）非小细胞肺癌（NSCLC）和基线脑转移（BM）：升降升降机Ascend-2试验

BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3

著录项

引文网络

相似文献

相关主题

期刊订阅